$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Portfolio Pulse from Avi Kapoor
Insiders are aggressively buying shares of Aclaris Therapeutics, Zomedica, and Perspective Therapeutics. This insider activity could indicate confidence in these companies' prospects. Aclaris posted upbeat quarterly results, Zomedica launched a new software update, and Perspective Therapeutics announced a reverse stock split.
June 14, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Perspective Therapeutics' CEO Johan M. Spoor acquired 100,000 shares at $1.17 each, totaling $117,430. The company announced a 1-for-10 reverse stock split on June 11.
While the insider purchase shows confidence, the reverse stock split could be seen as a mixed signal, leading to a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Aclaris Therapeutics' 10% owner Braden Michael Leonard bought 1,611,200 shares at $1.11 each, totaling $1.78 million. The company also posted upbeat quarterly results on May 7.
The significant insider purchase and recent positive quarterly results suggest strong confidence in the company's future, likely boosting short-term stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zomedica's VP of Sales Russell Kevin Klass acquired 299,993 shares at $0.16 each, totaling $46,529. The company recently launched an Over-the-Air software update for its TRUFORMA diagnostic platform.
The insider purchase and the launch of a new software update for a key product indicate potential growth, likely having a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100